COMMUNIQUÉS West-GlobeNewswire

Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program
17/10/2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today [...]
The Hemp Doctor Debuts 6.5G THC Disposable Vape: Bolder & Stronger Than Ever
17/10/2025
MOORESVILLE, N.C., Oct. 16, 2025 (GLOBE NEWSWIRE) -- The Hemp Doctor, a trusted leader in premium dispensary-grade hemp-derived products, has unveiled its latest innovation: the PHUK’D UP MEGA 6.5G THC Blend Disposable [...]
Junshi Biosciences Announces FDA’s Approval of IND Application for Phase 2/3 Clinical Study of JS207 for the Neoadjuvant Treatment of NSCLC Patients
17/10/2025
SHANGHAI, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, [...]
Le R&D Day de Cellectis souligne le potentiel de lasmé-cel pour combler un besoin médical majeur non satisfait chez les patients atteints de LAL-B en rechute ou réfractaire
16/10/2025
○ Efficacité : taux de réponse global (ORR) de 68 % avec le Process 2 de lasmé-cel (P2) (n=22) ; 83 % à la dose recommandée de Phase 2 (RP2D, n=12) ; et 100 % dans la population cible de Phase 2 (n=9) 1 ○ Sécurité : en [...]
Cellectis’ R&D Day Highlights Lasme-cel’s Potential to Address Significant Unmet Need for Patients with r/r B-ALL
16/10/2025
○ Efficacy: ORR of 68% with lasme-cel Process 2 (n=22), 83% at RP2D (n=12) and 100% in the target Phase 2 population (n=9) ○ Safety: in Phase 1 (n=40), lasme-cel was generally well-tolerated (including 1 case of grade 2 [...]
Praxis Precision Medicines, Inc. Announces Proposed Public Offering
16/10/2025
BOSTON, Oct. 16, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines , Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous [...]
Taysha Gene Therapies Regains Full Rights to Lead TSHA-102 Program in Clinical Evaluation for the Treatment of Rett Syndrome
16/10/2025
The 2022 Option Agreement between Astellas and Taysha has expired Regaining full rights to TSHA-102 Rett syndrome program enables Taysha to focus on driving its long-term value with full strategic flexibility and [...]
Galapagos Announces Appointment of Fred Blakeslee as General Counsel
16/10/2025
Mechelen, Belgium ; October 16, 2025, 22:01 CET; Galapagos NV (Euronext & NASDAQ: GLPG) today announced the appointment of Mr. Fred Blakeslee as Executive Vice President and General Counsel effective October 16, [...]
RxSight, Inc. to Feature Live Learning Sessions at American Academy of Ophthalmology 2025 Annual Meeting
16/10/2025
ALISO VIEJO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: RXST) RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, [...]
I-Mab Announces Intention to Undertake Strategic Transformation to Global Biotech Platform, to Pursue Hong Kong IPO, and Rebrand as NovaBridge Biosciences
16/10/2025
New business model reflects strategic transition to a global biotech platform focused on business development and translational clinical development to accelerate access to innovative medicines for patients worldwide [...]
Artiva Biotherapeutics Announces Refractory Rheumatoid Arthritis as Lead Indication, Upcoming Data Releases, and Corporate Update
16/10/2025
Prioritization of refractory rheumatoid arthritis (RA) as lead indication for AlloNK® development FDA Fast Track Designation received for AlloNK in refractory RA, representing the first drug candidate in the deep B-cell [...]
Seer to Report Third Quarter 2025 Financial Results on November 6, 2025
16/10/2025
REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the [...]
Lite Strategy Celebrates 14th Anniversary of Litecoin, Taps Institutional Signals Ahead of 2026
16/10/2025
Marking 14 years of continuous operation, millions of transactions, and demonstrated reliability across the global blockchain ecosystem, Litecoin sets the benchmark for longevity and performance as digital assets evolve [...]
WORK Medical Technology Group LTD Announces 1-for-100 Reverse Stock Split Effective October 21, 2025
16/10/2025
Hangzhou, China, Oct. 16, 2025 (GLOBE NEWSWIRE) -- WORK Medical Technology Group LTD (Nasdaq: WOK) (“WORK Medical” or the “Company”), a supplier of medical devices in China, through its subsidiary, Work (Hangzhou) [...]
LifeStance to Host Third Quarter 2025 Earnings Conference Call on November 6, 2025
16/10/2025
SCOTTSDALE, Ariz., Oct. 16, 2025 (GLOBE NEWSWIRE) -- LifeStance Health Group, Inc. (NASDAQ: LFST), one of the nation’s largest providers of outpatient mental health care, will issue its third quarter 2025 earnings [...]
atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression
16/10/2025
Breakthrough Therapy designation recognizes the potential of BPL-003 to deliver substantial improvement over existing therapies for patients with treatment-resistant depression FDA designation follows previously [...]
atai Life Sciences Announces Proposed Public Offering of Common Shares
16/10/2025
NEW YORK and AMSTERDAM, Oct. 16, 2025 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company focused on transforming the treatment of mental health [...]
Globus Medical Schedules Third Quarter Earnings Release and Conference Call
16/10/2025
AUDUBON, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Globus Medical , Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the third quarter ended September 30, 2025 after [...]
Teleflex Announces Third Quarter 2025 Earnings Conference Call Information and Vascular Intervention Investor Virtual Meeting Details
16/10/2025
WAYNE, Pa., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE:TFX) will host a conference call to discuss its third quarter financial results and provide an operational update at 8:00 a.m. Eastern Time on [...]

Pages